Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | SPR | P35270 | 2/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541504 | 0.94 | SYK (0.41) | SYKCNR2HSP90AA1HSP90AB1LRRK2 | |
| SCHEMBL541418 | 0.94 | SYK (0.41) | SYKCNR2HSP90AA1HSP90AB1LRRK2 | |
| SCHEMBL541503 | 0.94 | SYK (0.41) | SYKCNR2HSP90AA1HSP90AB1LRRK2 | |
| SCHEMBL541417 | 0.94 | SYK (0.41) | SYKCNR2HSP90AA1HSP90AB1LRRK2 | |
| SCHEMBL15397191 | 0.88 | SYK (0.36) | SYKCNR2HSD11B1SPR | |
| SCHEMBL15397160 | 0.82 | MAPK8 (0.37) | SYKHSD11B1 | |
| SCHEMBL541726 | 0.82 | HRH4 (0.42) | SYKHSD11B1SPR | |
| SCHEMBL541727 | 0.82 | HRH4 (0.42) | — | |
| SCHEMBL541766 | 0.82 | HRH4 (0.42) | SYKHSD11B1SPR | |
| SCHEMBL541767 | 0.82 | HRH4 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | SYK 1240/4885CNR2 1/4885HSP90AA1 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.